Neurotrophic Keratopathy After Herpes Zoster Ophthalmicus.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
received:
17
07
2021
accepted:
26
12
2021
pubmed:
5
2
2022
medline:
14
10
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
The aim of this study was to describe risk factors for neurotrophic keratopathy (NK) after herpes zoster ophthalmicus (HZO). This study was a retrospective review of all patients seen at the Auckland District Health Board with HZO from 2006 through 2016. Cox proportional hazards analysis was performed to examine time to development of neurotrophic keratitis. Eight hundred sixty-nine patients were included in the study with a median follow-up of 6.3 years (5504.4 patient-years). The median age was 65.5 years (interquartile range 52.9-75.4), and 456 subjects (52.5%) were male. NK developed in 58 patients (6.7%), with the highest hazard 1 to 2 years after onset of HZO. On univariate analysis, age, White ethnicity, best-corrected visual acuity (BCVA) at presentation, intraocular pressure, corneal involvement, uveitis, and number of recurrences were associated with increased risk of NK. On multivariate analysis, the following factors were significant: age (hazard ratio [HR] = 1.03; P = 0.021), White ethnicity (HR = 3.18; P = 0.015), BCVA (HR = 1.81; P = 0.026), uveitis (HR = 3.77; P = 0.001), and recurrence (HR = 1.34; P < 0.001). Vision loss (BCVA ≤6/15) was more frequent in subjects with NK (65.5% vs. 16.3%, P < 0.001). NK is a relatively common and serious complication of HZO and occurs more frequently in older White individuals, those with poor visual acuity at presentation, and those with uveitis. Vision loss occurs in approximately two-thirds of patients.
Identifiants
pubmed: 35120347
doi: 10.1097/ICO.0000000000003003
pii: 00003226-202211000-00014
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1433-1436Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Trinh T, Santaella G, Mimouni M, et al. Assessment of response to multimodal management of neurotrophic corneal disease. Ocul Surf. 2021;19:330–335.
Saad S, Abdelmassih Y, Saad R, et al. Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf. 2020;18:231–236.
Niederer RL, Meyer JJ, Liu K, et al. Herpes zoster ophthalmicus clinical presentation and risk factors for loss of vision. Am J Ophthalmol. 2021;226:83–89.
Cobo M, Foulks GN, Liesegang T, et al. Observations on the natural history of herpes zoster ophthalmicus. Curr Eye Res. 1987;6:195–199.
Mackie IA. Neuroparalytic keratitis. In: Fraunfelder FR, Meyer SM, eds. Current Ocular Therapy . Philadelphia, PA: WB Saunders; 1995.
Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
Gilden D, Nagel MA, Cohrs RJ, et al. The variegate neurological manifestations of varicella zoster virus infection. Curr Neurol Neurosci Rep. 2013;13:374.
Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928–930.
Marsh RJ, Cooper M. Ophthalmic herpes zoster. Eye. 1993;7:350–370.
Tullo AB, Johnson RW, Easty DL. Corneal hyperesthesia after herpes zoster ophthalmicus. Cornea. 1983;2:115–118.
Bonini S, Rama P, Olzi D, et al. Neurotrophic keratitis. Eye. 2003;17:989–995.
Cobo LM. Corneal complications of herpes zoster ophthalmicus. Prevention and treatment. Cornea. 1988;7:50–56.
Liesegang TJ. Corneal complications from herpes zoster ophthalmicus. Ophthalmology. 1985;92:316–324.
Hamrah P, Cruzat A, Dastjerdi MH, et al. Unilateral herpes zoster ophthalmicus results in bilateral corneal nerve alteration: an in vivo confocal microscopy study. Ophthalmology. 2013;120:40–47.
Kahloun R, Attia S, Jelliti B, et al. Ocular involvement and visual outcome of herpes zoster ophthalmicus: review of 45 patients from Tunisia, North Africa. J Ophthalmic Inflamm Infect. 2014;4:25.
Ghaznawi N, Virdi A, Dayan A, et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. Ophthalmology. 2011;118:2242–2250.
Tran KD, Falcone MM, Choi DS, et al. Epidemiology of herpes zoster ophthalmicus: recurrence and chronicity. Ophthalmology. 2016;123:1469–1475.
Pflugfelder SC, Massaro-Giordano M, Perez VL, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial. Ophthalmology. 2020;127:14–26.
Trollip JC, Meyer JJ, McGhee CN, et al. Ethylenediaminetetraacetic acid chelation in herpes zoster ophthalmicus is associated with a high rate of corneal melt and perforation. Cornea. 2021;40:277–281.
Lu LM, McGhee CN, Sims JL, et al. High rate of recurrence of herpes zoster-related ocular disease after phacoemulsification cataract surgery. J Cataract Refract Surg. 2019;45:810–815.
Soong HK, Schwartz AE, Meyer RF, et al. Penetrating keratoplasty for corneal scarring due to herpes zoster ophthalmicus. Br J Ophthalmol. 1989;73:19–21.
Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol. 2011;174:1054–1061.